# Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

Study · id `cardio:ct-nct02983214` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02983214](<https://clinicaltrials.gov/study/NCT02983214>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02983214

Browse, organ or system: Blood vessels; Brain; Metabolism  
Browse, condition area: Coronary and vascular disease; Stroke; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 826 participants.

## Technical summary

Registry record NCT02983214. Randomized; no masking; primary purpose health services research. Start 2016-11 (actual); primary completion 2019-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose health services research
- Phase: Phase 4
- Enrolled: 826 participants (enrolled count; ClinicalTrials.gov record NCT02983214, source copy `cardio:ctgov-nct02983214-2020-12-29`, retrieved 2026-10-26)
- Started: 2016-11 (actual) (ClinicalTrials.gov record NCT02983214, source copy `cardio:ctgov-nct02983214-2020-12-29`, retrieved 2026-10-26)
- Primary completion: 2019-10 (actual) (ClinicalTrials.gov record NCT02983214, source copy `cardio:ctgov-nct02983214-2020-12-29`, retrieved 2026-10-26)
- Completion: 2019-10 (actual) (ClinicalTrials.gov record NCT02983214, source copy `cardio:ctgov-nct02983214-2020-12-29`, retrieved 2026-10-26)
- Countries: Greece (ClinicalTrials.gov record NCT02983214, source copy `cardio:ctgov-nct02983214-2020-12-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02983214-2020-12-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
- Acronym: DORIC
- Condition: Ischemic Stroke
- Condition: Peripheral Artery Disease
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Cilostazol
- Lead sponsor: University of Ioannina
- Lead sponsor class: OTHER
- Collaborator: LIBYTEC Pharmaceutical S.A.
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: University of Ioannina (`cardio:org-university-of-ioannina`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Adjunctive Cilostazol to Clopidogrel-Treated Diabetic Patients With Symptomatic Lower Extremity Artery Disease in the Prevention of Ischemic Vascular Events (`cardio:pubmed-33327737`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 4189cd70a0c78927a4fec37ba9223639062b35388d9ea1a5dece9f5509311c93
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
